Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: Implications for the emergence and reversal of cancer drug resistance

(A) ABCG2 confers gefitinib or pelitinib resistance. Intracellular efficiency of neratinib or vandetanib is not restricted by ABCG2. (B) EGFR inhibitors block ABCG2 function thereby reversing MDR.